As of November 8, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Alto Neuroscience Inc. The largest reported stake is Perceptive Advisors LLC's, at 9.99%. 21 filings are on record since July 16, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Alto Neuroscience Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Vanguard Capital Management · Sole voting: 279,355 · Shared voting: 0 · Sole dispositive: 1,970,108 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-30
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 4,176,711 · Sole dispositive: 0 · Shared dispositive: 4,176,711 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Sirenia Capital Management LP · Sole voting: 0 · Shared voting: 2,219,568 · Sole dispositive: 0 · Shared dispositive: 2,219,568 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Vestal Point Capital, LP · Sole voting: 0 · Shared voting: 785,000 · Sole dispositive: 0 · Shared dispositive: 785,000 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 2,077,542 · Shared voting: 0 · Sole dispositive: 2,104,406 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-27
Alto Neuroscience Inc has 21 Schedule 13D or 13G filings on record since 2025-07-16. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Perceptive Advisors LLC | 9.99% | 4,176,711 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Commodore Capital LP | 9.9% | 3,588,180 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Sirenia Capital Management LP | 6.2% | 2,219,568 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 6% | 2,104,406 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| EcoR1 Capital, LLC | 5.8% | 2,232,000 | SCHEDULE 13G, 2026-07-20 | 2026-07-13 |
| Vanguard Capital Management | 5.02% | 1,970,108 | SCHEDULE 13G, 2026-10-30 | 2026-09-30 |
| Armistice Capital, LLC | 4.94% | 1,536,000 | SCHEDULE 13G/A, 2026-02-18 | 2025-12-31 |
| 3.7% | 1,170,865 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 | |
| K2 HealthVentures Equity Trust LLC | 2.4% | 788,995 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Vestal Point Capital, LP | 2.2% | 785,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Alto Neuroscience Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Alto Neuroscience Inc and the records around it.
Alto Neuroscience Inc elsewhere on the record
- Leadership changes Aug 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- K2 HealthVentures Equity Trust LLC also filed stake reports on 1 other company: Neumora Therapeutics, Inc. (May 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026), Design Therapeutics, Inc. (Aug 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Fulcrum Therapeutics, Inc. (Jun 2026), Eloxx Pharmaceuticals, Inc. (Jun 2026)
Watch Alto Neuroscience Inc
Get an email when Alto Neuroscience Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Alto Neuroscience Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Alto Neuroscience Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alto Neuroscience Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
24 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 0 | 4,176,711 | 0 | 4,176,711 | SCHEDULE 13G/A, 2026-08-14 |
| Joseph Edelman | 0 | 4,176,711 | 0 | 4,176,711 | SCHEDULE 13G/A, 2026-08-14 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 4,176,711 | 0 | 4,176,711 | SCHEDULE 13G/A, 2026-08-14 |
| Sirenia Capital Management LP | 0 | 2,219,568 | 0 | 2,219,568 | SCHEDULE 13G/A, 2026-08-14 |
| Alex Silverstein | 0 | 2,219,568 | 0 | 2,219,568 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 2,077,542 | 0 | 2,104,406 | 0 | SCHEDULE 13G, 2026-07-27 |
| EcoR1 Capital, LLC | 0 | 2,232,000 | 0 | 2,232,000 | SCHEDULE 13G, 2026-07-20 |
| Oleg Nodelman | 0 | 2,232,000 | 0 | 2,232,000 | SCHEDULE 13G, 2026-07-20 |
| EcoR1 Capital Fund Qualified, L.P. | 0 | 2,065,935 | 0 | 2,065,935 | SCHEDULE 13G, 2026-07-20 |
| Vanguard Capital Management | 279,355 | 0 | 1,970,108 | 0 | SCHEDULE 13G, 2026-10-30 |
| Vestal Point Capital, LP | 0 | 785,000 | 0 | 785,000 | SCHEDULE 13G/A, 2026-08-14 |
| Ryan Wilder | 0 | 785,000 | 0 | 785,000 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Alto Neuroscience Inc by CUSIP 02157Q109 and gives its principal executive office as 369 S San Antonio Rd, Los Altos, CA 94022 (SCHEDULE 13G, 2026-10-30).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 2.1% | SCHEDULE 13G/A |
| 2025-08-14 | Armistice Capital, LLC | 6% | SCHEDULE 13G/A |
| 2025-10-10 | Perceptive Advisors LLC | 7.3% | SCHEDULE 13G |
| 2025-10-27 | Commodore Capital LP | 9.8% | SCHEDULE 13G |
| 2026-02-17 | Vestal Point Capital, LP | 8% | SCHEDULE 13G |
| 2026-02-17 | Steven A. Cohen | 8.9% | SCHEDULE 13G/A |
| 2026-02-17 | K2 HealthVentures Equity Trust LLC | 2.4% | SCHEDULE 13G/A |
| 2026-02-17 | Armistice Capital, LLC | 6% | SCHEDULE 13G/A |
| 2026-02-17 | Perceptive Advisors LLC | 9.99% | SCHEDULE 13G/A |
| 2026-02-17 | Commodore Capital LP | 9.9% | SCHEDULE 13G/A |
| 2026-02-18 | Armistice Capital, LLC | 4.94% | SCHEDULE 13G/A |
| 2026-05-15 | Vestal Point Capital, LP | 6.5% | SCHEDULE 13G/A |
| 2026-05-15 | Sirenia Capital Management LP | 7.9% | SCHEDULE 13G |
| 2026-05-15 | Steven A. Cohen | 3.7% | SCHEDULE 13G/A |
| 2026-05-15 | Commodore Capital LP | 9.9% | SCHEDULE 13G/A |
| 2026-07-20 | EcoR1 Capital, LLC | 5.8% | SCHEDULE 13G |
| 2026-07-27 | BlackRock, Inc. | 6% | SCHEDULE 13G |
| 2026-08-14 | Vestal Point Capital, LP | 2.2% | SCHEDULE 13G/A |
| 2026-08-14 | Sirenia Capital Management LP | 6.2% | SCHEDULE 13G/A |
| 2026-08-14 | Perceptive Advisors LLC | 9.99% | SCHEDULE 13G/A |
| 2026-10-30 | Vanguard Capital Management | 5.02% | SCHEDULE 13G |
Questions about who owns Alto Neuroscience Inc
Who owns Alto Neuroscience Inc?
On this page, 6 holders' latest ownership filings report 5% or more of Alto Neuroscience Inc: Perceptive Advisors LLC (9.99%, Schedule 13G/A, filed 2026-08-14), Commodore Capital LP (9.9%, Schedule 13G/A, filed 2026-05-15), Sirenia Capital Management LP (6.2%, Schedule 13G/A, filed 2026-08-14), BlackRock, Inc. (6%, Schedule 13G, filed 2026-07-27) and EcoR1 Capital, LLC (5.8%, Schedule 13G, filed 2026-07-20); 1 more is listed above.
Who are the largest shareholders of Alto Neuroscience Inc?
By the share each holder's latest filing reports, the largest holders of Alto Neuroscience Inc on this page are Perceptive Advisors LLC (9.99%), Commodore Capital LP (9.9%) and Sirenia Capital Management LP (6.2%).
When did Perceptive Advisors LLC buy into Alto Neuroscience Inc?
The filings give report dates, not purchase dates. The earliest filing from Perceptive Advisors LLC on this page is the Schedule 13G, filed 2025-10-10, reporting 7.3%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 21 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Alto Neuroscience Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 27, 2026 | Leadership change: Nicholas C. Smith appointed, Chief Financial Officer and Chief Business Officer | — | Leadership changes | Source |
| May 28, 2026 | Leadership change: Andrew Miller appointed, Director, and 1 more | — | Leadership changes | Source |
| October 27, 2025 | Form D, private offering | $50M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Alto Neuroscience Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.